Seeking Alpha

More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of...

More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR)

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (1)
  • Trosie
    , contributor
    Comment (1) | Send Message
    As someone who has closely invested in and watched REGN over almost 20 years, I am thrilled but not surprised that this innovative, disciplined, and well-managed company has begun to reap the fruits of its labors. While there are many challenges ahead, and granted I am not an expert in the field of biotech, I do believe, based on sound data about this company and its products, that this is only the beginning of a very, very, good ride.
    14 Feb 2013, 08:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs